Impact of the apolipoprotein B/apolipoprotein A-I ratio on renal outcome in immunoglobulin A nephropathy

Scandinavian Journal of Urology and Nephrology

Volumn 46, Issue 2, 2012, Pages 148-155

  Lundberg, S ^a   Gunnarsson, I ^a   Jacobson, S H ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b DANDERYD HOSPITAL   (Sweden)

Author keywords

Apolipoproteins; Chronic renal disease; IgA nephropathy; Prognostic factor

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; SERUM ALBUMIN;

ADULT; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENDER; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; HIGH RISK PATIENT; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

ADULT; ALBUMINURIA; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; BLOOD PRESSURE; C-REACTIVE PROTEIN; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS, IGA; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SERUM ALBUMIN;

EID: 84858397676     PISSN: 00365599     EISSN: 16512065     Source Type: Journal    
DOI: 10.3109/00365599.2011.644635     Document Type: Article

References (44)

1. D'Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med 1987;64:709-27. (Pubitemid 18047151)
2. Coppo R, D'Amico G. Factors predicting progression of IgA nephropathies. J Nephrol 2005;18:503-12. (Pubitemid 41824469)
3. Myllymaki J, Syrjanen J, Helin H, Pasternack A, Kattainen A, Mustonen J. Vascular diseases and their risk factors in IgA nephropathy. Nephrol Dial Transplant 2006;21:1876-82. (Pubitemid 43985716)
4. Diamond JR. Analogous pathobiologic mechanisms in glo-merulosclerosis and atherosclerosis. Kidney Int 1991;31: S29-34.
5. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002;106: 1777-82.
6. Weir MR. Microalbuminuria and cardiovascular disease. Clin J Am Soc Nephrol 2007;2:581-90.
7. Law MR, Wald NJ. Risk factor thresholds: their existence under scrutiny. BMJ 2002;324:1570-6. (Pubitemid 34713139)
8. Wallis EJ, Ramsay LE, Ul Haq I, Ghahramani P, Jackson PR, Rowland-Yeo K, et al. Coronary and cardiovascular risk estimation for primary prevention: validation of a new Sheffield table in the 1995 Scottish health survey population. BMJ 2000;320:671-6.
9. Lamarche B, Moorjani S, Lupien PJ, Cantin B, Bernard PM, Dagenais GR, et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study. Circulation 1996; 94:273-8. (Pubitemid 26266109)
10. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001;358: 2026-33. (Pubitemid 34084825)
11. Walldius G, Jungner I, Aastveit AH, Holme I, Furberg CD, Sniderman AD. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clin Chem Lab Med 2004;42:1355-63. (Pubitemid 40057822)
12. Sierra-Johnson J, Fisher RM, Romero-Corral A, Somers VK, Lopez-Jimenez F, Ohrvik J, et al. Concentration of apolipo-protein B is comparable with the apolipoprotein B/apolipo-protein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multi-ethnic US population. Eur Heart J 2009;30:710-17.
13. Attman PO, Alaupovic P, Gustafson A. Serum apolipopro-tein profile of patients with chronic renal failure. Kidney Int 1987;32:368-75. (Pubitemid 17147883)
14. Lee DM, Knight-Gibson C, Samuelsson O, Attman PO, Wang CS, Alaupovic P. Lipoprotein particle abnormalities and the impaired lipolysis in renal insufficiency. Kidney Int 2002;61:209-18. (Pubitemid 34075149)
15. Fournier A, Achard JM. Mnemotechnical note on the use of Cockcroft creatinine clearance formula for the validation of a 24-h urine collection. Nephrol Dial Transplant 2000;15: 1677-8.
16. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247-54. (Pubitemid 46768608)
17. Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med 2004;255:188-205. (Pubitemid 38241363)
18. Lind L, Vessby B, Sundstrom J. The apolipoprotein B/AI ratio and the metabolic syndrome independently predict risk for myocardial infarction in middle-aged men. Arterioscler Thromb Vasc Biol 2006;26:406-10. (Pubitemid 43732207)
19. Wallenfeldt K, Bokemark L, Wikstrand J, Hulthe J, Fagerberg B. Apolipoprotein B/apolipoprotein A-I in relation to the metabolic syndrome and change in carotid artery intima-media thickness during 3 years in middle-aged men. Stroke 2004;35:2248-52. (Pubitemid 39311244)
20. Kaartinen K, Syrjanen J, Porsti I, Hurme M, Harmoinen A, Pasternack A, et al. Inflammatory markers and the progression of IgA glomerulonephritis. Nephrol Dial Transplant 2008;23:1285-90. (Pubitemid 351767501)
21. Keller C, Katz R, Sarnak MJ, Fried LF, Kestenbaum B, Cushman M, et al. Inflammatory biomarkers and decline in kidney function in the elderly: the Cardiovascular Health Study. Nephrol Dial Transplant 2010;25:119-24.
22. Bonnet F, Deprele C, Sassolas A, Moulin P, Alamartine E, Berthezene F, et al. Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis. Am J Kidney Dis 2001;37:720-7. (Pubitemid 32268032)
23. Marcovina S, Packard CJ. Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels. J Intern Med 2006;259:437-46.
24. Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipi-d-lowering therapy-a review of the evidence. J Intern Med 2006;259:493-519.
25. Barter PJ, Ballantyne CM, Carmena R, Castro Cabezas M, Chapman MJ, Couture P, et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med 2006; 259:247-58.
26. Quaschning T, Krane V, Metzger T, Wanner C. Abnormalities in uremic lipoprotein metabolism and its impact on cardiovascular disease. Am J Kidney Dis 2001;38(4 Suppl 1):S14-19. (Pubitemid 32927605)
27. Sniderman AD, Jungner I, Holme I, Aastveit A, Walldius G. Errors that result from using the TC/HDL C ratio rather than the apoB/apoA-I ratio to identify the lipoprotein-related risk of vascular disease. J Intern Med 2006;259:455-61.
28. Sniderman AD. How, when, and why to use apolipoprotein B in clinical practice. Am J Cardiol 2002;90:48-54i.
29. Rader DJ, Davidson MH, Caplan RJ, Pears JS. Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin. Am J Cardiol 2003;91:20-3C; discussion 3-4C.
30. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000.
31. Schmidt C, Wikstrand J. High apoB/apoA-I ratio is associated with increased progression rate of carotid artery inti-ma-media thickness in clinically healthy 58-year-old men: experiences from very long-term follow-up in the AIR study. Atherosclerosis 2009;205:284-9.
32. Juonala M, Viikari JS, Kahonen M, Solakivi T, Helenius H, Jula A, et al. Childhood levels of serum apolipoproteins B and A-I predict carotid intima-media thickness and brachial endothelial function in adulthood: the cardiovascular risk in young Finns study. J Am Coll Cardiol 2008;52:293-9. (Pubitemid 351957853)
33. Morales E, Valero MA, Leon M, Hernandez E, Praga M. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis 2003; 41:319-27. (Pubitemid 36152449)
34. Shen WW, Chen HM, Chen H, Xu F, Li LS, Liu ZH. Obesity-related glomerulopathy: body mass index and pro-teinuria. Clin J Am Soc Nephrol 2010;4:1401-9.
35. Musunuru K. Atherogenic dyslipidemia: cardiovascular risk and dietary intervention. Lipids 2010;45:907-14.
36. Campese VM, Park J. HMG-CoA reductase inhibitors and renal function. Clin J Am Soc Nephrol 2007;2:1100-3.
37. Fried LF. Effects of HMG-CoA reductase inhibitors (statins) on progression of kidney disease. Kidney Int 2008;74:571-6.
38. Lundberg S, Lundahl J, Gunnarsson I, Jacobson SH. Ator-vastatin-induced modulation of monocyte respiratory burst in vivo in patients with IgA nephropathy: a chronic inflammatory kidney disease. Clin Nephrol 2010;73:221-8.
39. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 2006;17:2006-16. (Pubitemid 44036185)
40. Tonelli M, Moye L, Sacks FM, Cole T, Curhan GC. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 2003;14:1605-13. (Pubitemid 36687063)
41. Kassimatis TI, Konstantinopoulos PA. The role of statins in chronic kidney disease (CKD): friend or foe? Pharmacol Ther 2009;122:312-23.
42. Navaneethan SD, Pansini F, Perkovic V, Manno C, Pellegrini F, Johnson DW, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2009: CD007784.
43. Strippoli GF, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regres-sion of randomised controlled trials. BMJ 2008;336:645-51. (Pubitemid 351481234)
44. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377: 2181-92.